Fortsatt hög organisk tillväxt Lagercrantz rapporterade 10% organisk tillväxt i Q3 och även om tillv...
Redeye comments on Kontigo Cares Q4'22 report, in which Net Sales (SEK7.
Suominen’s Q4 results remained below estimates. Top line grew 15% y/y but was still soft relative to...
Redeye provides its initial take on Mentice’s Q4 2022 report, which came in broadly below our estima...
Redeye konstaterar att BioArctics Q4-rapport kom in i linje med förväntan, med ett resultat på SEK -...
Redeye sees a solid Q4 report from Addnode with strong organic and acquired growth.
SRV enters difficult market with a low-risk project portfolio and a healthy balance sheet.
CapMan’s operative performance in Q4 was quite decent with the big surprise being the divestment of ...
We cut '23e-'24e EBITA by 4% Management cautiously optimistic on price increases Macroeconomic condi...
Redeye updates its view on Evolution post Q4-results which came in just above our expectations and w...
Redeye states Sivers Q4'22 report and guidance was largely inline with our estimates.
Redeye provides a preview ahead of Fragbite Groups Q4 report, due on 23th February, where we slightl...
CapMan reported Q4 adjusted EBIT of EUR 10.1m, in line with Refinitiv consensus.
FY'22 PTP guidance DKK ~600m, at high end of the old range Strong Q4e based on 21% NII growth q-o-q ...
Redeye notes that Fram Skandinavien continues to deliver according to its strategic plan and slowly ...
Q4e: EBITDA of NOK 17.9m Margins set to rise in '23e on lower e-com investments '23e adj.
After a period with pressure on margins and especially the organic growth, the 11% organic growth in...
Stronger than expected sales but weak EBIT FDA's observations in the US being addressed Conference c...
Redeye’s first comments following this morning’s Q4 report for Tagmaster.
CapMan reported Q4 EBIT of 7.5m, 26% below Refinitiv consensus.
